Updates in Cardiac Amyloidosis: a Review

Overview

Journal J Am Heart Assoc

Specialty Cardiology & Vascular Diseases

Date 2012 Nov 7

PMID 23130126

Citations 105

Authors

Sanjay M Banypersad

James C Moon

Carol Whelan

Philip N Hawkins

Ashutosh D Wechalekar

Affiliations

Soon will be listed here.

Citing Articles

Advances and challenges in echocardiographic diagnosis and management of cardiac amyloidosis.

Tian Y, Liu H Int J Cardiovasc Imaging. 2025; .

PMID: 40009119 DOI: 10.1007/s10554-025-03362-5.

Prevalence of transthyretin cardiac amyloidosis in patients with aortic stenosis.

SadrAldin R, Ahmed J, Alkaf F, Ahmed M, Mousa Z, AlQahtani S Am J Cardiovasc Dis. 2025; 14(6):384-395.

PMID: 39839566 PMC: 11744221. DOI: 10.62347/HJHT9161.

Deep learning model to diagnose cardiac amyloidosis from haematoxylin/eosin-stained myocardial tissue.

Tohyama T, Iwasaki T, Ikeda M, Katsuki M, Watanabe T, Misumi K Eur Heart J Imaging Methods Pract. 2025; 3(1):qyae141.

PMID: 39811011 PMC: 11728699. DOI: 10.1093/ehjimp/qyae141.

Assessing microvascular dysfunction and predicting long-term prognosis in patients with cardiac amyloidosis by cardiovascular magnetic resonance quantitative stress perfusion.

Tang L, Zhao W, Li K, Tian L, Zhou X, Guo H J Cardiovasc Magn Reson. 2024; 27(1):101134.

PMID: 39675481 PMC: 11761856. DOI: 10.1016/j.jocmr.2024.101134.

A Quantitative Diagnostic Method Using Tc-pyrophosphate Lateral Planar Images to Distinguish Between Transthyretin Amyloid Cardiomyopathy and False-Positive Images Due to Blood Pools.

Hara J, Ishii S, Kobiyama H, Fukushima K, Kawamoto N, Yamakuni R Ann Nucl Cardiol. 2024; 10(1):23-28.

PMID: 39635326 PMC: 11612392. DOI: 10.17996/anc.24-00001.

References

Navarro J, Rivera M, Ortuno J . Cardiac tamponade as presentation of systemic amyloidosis. Int J Cardiol. 1992; 36(1):107-8. DOI: 10.1016/0167-5273(92)90115-j. View

Hawkins P, LAVENDER J, Pepys M . Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med. 1990; 323(8):508-13. DOI: 10.1056/NEJM199008233230803. View

Abdelmoneim S, Bernier M, Bellavia D, Syed I, Mankad S, Chandrasekaran K . Myocardial contrast echocardiography in biopsy-proven primary cardiac amyloidosis. Eur J Echocardiogr. 2008; 9(2):338-41. DOI: 10.1093/ejechocard/jen017. View

Cohen A, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H . Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol. 2007; 139(2):224-33. DOI: 10.1111/j.1365-2141.2007.06783.x. View

Wechalekar A, Gillmore J, Wassef N, Lachmann H, Whelan C, Hawkins P . Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of cardiac amyloidosis. Haematologica. 2011; 96(7):1079-80. PMC: 3128232. DOI: 10.3324/haematol.2011.040493. View

Austin B, Tang W, Rodriguez E, Tan C, Flamm S, Taylor D . Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging. 2010; 2(12):1369-77. DOI: 10.1016/j.jcmg.2009.08.008. View

Gutierrez P, Fernandes F, Mady C, Higuchi M . Clinical, electrocardiographic and echocardiographic findings in significant cardiac amyloidosis detected only at necropsy: comparison with cases diagnosed in life. Arq Bras Cardiol. 2008; 90(3):191-6. DOI: 10.1590/s0066-782x2008000300009. View

Murtagh B, Hammill S, Gertz M, Kyle R, Tajik A, Grogan M . Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005; 95(4):535-7. DOI: 10.1016/j.amjcard.2004.10.028. View

Falk R . Diagnosis and management of the cardiac amyloidoses. Circulation. 2005; 112(13):2047-60. DOI: 10.1161/CIRCULATIONAHA.104.489187. View

10.

Bellavia D, Pellikka P, Abraham T, Al-Zahrani G, Dispenzieri A, Oh J . 'Hypersynchronisation' by tissue velocity imaging in patients with cardiac amyloidosis. Heart. 2008; 95(3):234-40. DOI: 10.1136/hrt.2007.140343. View

11.

Ogiwara F, Koyama J, Ikeda S, Kinoshita O, Falk R . Comparison of the strain Doppler echocardiographic features of familial amyloid polyneuropathy (FAP) and light-chain amyloidosis. Am J Cardiol. 2005; 95(4):538-40. DOI: 10.1016/j.amjcard.2004.10.029. View

12.

Woodrow S, Stewart R, Kisilevsky R, Gore J, Young I . Experimental AA amyloidogenesis is associated with differential expression of extracellular matrix genes. Amyloid. 1999; 6(1):22-30. DOI: 10.3109/13506129908993284. View

13.

Bellavia D, Pellikka P, Abraham T, Al-Zahrani G, Dispenzieri A, Oh J . Evidence of impaired left ventricular systolic function by Doppler myocardial imaging in patients with systemic amyloidosis and no evidence of cardiac involvement by standard two-dimensional and Doppler echocardiography. Am J Cardiol. 2008; 101(7):1039-45. DOI: 10.1016/j.amjcard.2007.11.047. View

14.

Kisilevsky R . The relation of proteoglycans, serum amyloid P and apo E to amyloidosis current status, 2000. Amyloid. 2000; 7(1):23-5. DOI: 10.3109/13506120009146820. View

15.

Maceira A, Joshi J, Prasad S, Moon J, Perugini E, Harding I . Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005; 111(2):186-93. DOI: 10.1161/01.CIR.0000152819.97857.9D. View

16.

Connors L, Lim A, Prokaeva T, Roskens V, Costello C . Tabulation of human transthyretin (TTR) variants, 2003. Amyloid. 2003; 10(3):160-84. DOI: 10.3109/13506120308998998. View

17.

Dhoble A, Khasnis A, Olomu A, Thakur R . Cardiac amyloidosis treated with an implantable cardioverter defibrillator and subcutaneous array lead system: report of a case and literature review. Clin Cardiol. 2009; 32(8):E63-5. PMC: 6653454. DOI: 10.1002/clc.20389. View

18.

Feng D, Syed I, Martinez M, Oh J, Jaffe A, Grogan M . Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation. 2009; 119(18):2490-7. DOI: 10.1161/CIRCULATIONAHA.108.785014. View

19.

Kristen A, Dengler T, Hegenbart U, Schonland S, Goldschmidt H, Sack F . Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm. 2008; 5(2):235-40. DOI: 10.1016/j.hrthm.2007.10.016. View

20.

Westermark P, Sletten K, Johansson B, CORNWELL 3rd G . Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A. 1990; 87(7):2843-5. PMC: 53787. DOI: 10.1073/pnas.87.7.2843. View